Aspen Biosciences

reduce risk & costs, and improve communications & collaborations both inside and outside of the company.

YouTube video by Aspen Biosciences Pipeline Overview

Got 8 minutes? Let us show you how the Pipeline Drug Discovery platform can transform your research operations...

#Biotech #DrugDiscovery #workflows #AI #ProteinProduction #Chemistry #AssayManagement #Registration #Inventory

YouTube video by Aspen Biosciences Aspen Overview

At Aspen Biosciences provide drug discovery companies with the tools they need to create new medicines. To learn more, visit us at aspen.bio or contact us at info@aspen.bio

youtu.be/lTSJXGEivM0

YouTube video by Aspen Biosciences AI State of Play 2025

Got 8 minutes? Want to find out how #AI is transforming #DrugDiscovery? Click here to watch the video. youtu.be/4BDoeGxy_ns?...

Got 20 minutes? Click here to download the white paper. drive.google.com/file/d/1a6et...

Need to transform your research operations? Contact us info@aspen.bio

Is your AI strategy stuck in "Pilot Purgatory"? 🧬💻

Our new whitepaper "From Hype To Implementation" deconstructs the biopharma AI success story from hype to clinical implementation.

bit.ly/3YzVNa2

#DrugDiscovery #GenAI #Biotech #AI

The AI State of Play 2025 highlights a watershed year where AI-discovered molecules achieved Phase I clinical success rates of 80-90%, significantly outperforming the historical average of 40-65%. The report identifies five structural pillars: Big Pharma "AI Factories": Companies like Eli Lilly and Pfizer are building massive internal computational infrastructures and reducing discovery timelines for small molecules to just 30 days. TechBio Maturity: Companies like Insilico Medicine achieved a "Penicillin Moment" with positive Phase 2a results for the first entirely AI-native drug. Democratized Modeling: Open-source tools like Boltz-2 and OpenFold3 have commoditized high-accuracy molecular modeling. The "Agentic" Shift: A move toward autonomous systems that can independently formulate hypotheses and execute experiments. Regulatory Adaptation: Increased focus on biologics (13-year protection) over small molecules (9-year protection) due to the Inflation Reduction Act (IRA). Download the AI State of Play 2025 to learn more: https://drive.google.com/file/d/1a6etlnbgWyC2PbZIZGGXWLCJ-saA4BSO/view?usp=drive_link AI State of Play 2025

The 2025 AI State of Play is here. 🧬 AI-native drugs are hitting 80-90% Phase I success rates, fundamentally challenging Eroom's Law. This short video explainer fills in the details.

youtu.be/4BDoeGxy_ns

#AI #DrugDiscovery

State of Play 2025 What does the "State of Play" look like for the biotech and pharma industry in 2025? In this explainer, we take a look at some of the changes over the last year—from a resurgence in funding for high-value assets to the incredible speed of AI-driven drug discovery (did you know Pfizer is hitting 30-day discovery cycles?). For more details, read our free State of Play 2025 whitepaper. https://drive.google.com/file/d/1E1y6RRas74I2a4A1lFhZwZE2F9sDQucH/view?usp=drive_link

The biotech industry entered a phase of "disciplined resilience" in 2025. While venture funding is rebounding—surging 70% in Q3 alone—the capital is being tethered to clinical validation like never before.

This explainer gives you all of the highlights.
bit.ly/3NfNn59

The Digital Transformation Roadmap - Aspen Biosciences The whitepaper explores the impact of digital transformation on small molecule drug discovery, highlighting strategies to enhance R&D efficiency and reduce costs. It includes case studies,and practical approaches aimed at boosting capital efficiency and accelerating the delivery of innovative therapies to patients. What you'll learn in the whitepaper: Digital transformation is the process of applying technologies like AI, automation and advanced analytics to fundamentally change drug discovery, in ways that measurably reduce costs and timelines, improve capital efficiency and create a more lean and agile research organization. This paper provides case studies, and practical strategies to drive -

#DigitalTransformation is the process of applying #AI, #automation and advanced analytics to measurably reduce #DrugDiscovery costs and timelines, improve capital efficiency and create a more lean and agile research organization.

bit.ly/495vIG2

AI-native drugs are hitting 80-90% Phase I success rates. From Pfizer's 30-day discovery cycle to the rise of Agentic AI, see how #AI is transforming #DrugDiscovery.

drive.google.com/file/d/1a6et...

#TechBio #BioPharma #JPM26 #JPM

The 2025 Biotech "State of Play" is here. 🔬 We’re seeing massive shifts: AI-Driven Improvements in productivity, timelines, and success rates. M&A deal values up 31%. $350B in rev. at risk by 2029. Ready for recalibration? https://drive.google.com/file/d/1E1y6RRas74I2a4A1lFhZwZE2F9sDQucH/view?usp=drive_link #LifeSciences #Biotech #Innovation

The 2025 Biotech "State of Play" is here. 🔬
We’re seeing massive shifts:
AI-Driven Improvements in productivity, timelines, and success rates.
M&A deal values up 31%.
$350B in rev. at risk by 2029.
Ready for recalibration?
drive.google.com/file/d/1E1y6...

#Biotech #Innovation #AI #JPM26

The Trump administration is dismantling efforts to fight the next pandemic A retreat from investments in drugs and vaccines leaves U.S. less prepared for the next viral scourge, experts warn

A retreat from investments in drugs and vaccines will leave the U.S. less prepared for the next viral scourge, experts warn. https://scim.ag/47F3Yap

We're excited to present LeaVS, a method to scale up learning for protein function models. It is based on the co-design of wet lab experiments and in silico training.

AI models that lie, cheat and plot murder: how dangerous are LLMs really? Tests of large language models reveal that they can behave in deceptive and potentially harmful ways. What does this mean for the future?

Tests of large language models reveal that they can behave in deceptive and potentially harmful ways. Nature reports on what these results mean for the future of AI. 🧪

The Digital Transformation Roadmap - Aspen Biosciences The whitepaper explores the impact of digital transformation on small molecule drug discovery, highlighting strategies to enhance R&D efficiency and reduce costs. It includes case studies,and practica...

Check out our latest whitepaper on Digital Transformations and learn how you can apply these technologies to improve your own drug discovery process. aspenbiosciences.com/whitepapers/...

Despite all of the uncertainty in the industry, those two elements continue to be a high priority for investors. They want to know how you're going to get the rest of your pipeline across the finish the line in the most capital efficient manner possible.

The past couple of years have been challenging for biotech companies. At #JPM2025, investors were looking for two things: Phase II results, and a #DigitalTransformation story that showed how #AI, #automation and advanced analytics would be used to advance early stage programs into the clinic.

The Digital Transformation Roadmap - Aspen Biosciences The whitepaper explores the impact of digital transformation on small molecule drug discovery, highlighting strategies to enhance R&D efficiency and reduce costs. It includes case studies,and practica...

The race for funding is real, but chaos isn't a plan. It's time to swap out the monkeys for a real digital transformation roadmap.

aspenbiosciences.com/whitepapers/...

YouTube video by Aspen Biosciences Digital Transformation with Robot Monkeys

Does your drug discovery strategy feel like... AI-fueled robot monkeys hammering away and hoping for a miracle? 🐒🤖

youtu.be/R0n__5HOOe8?...

#Biotech #DrugDiscovery #Pharma #DigitalTransformation #AI #Automation #Science

Visualization in Jmol of hemoglobin. The four protein strands (cartoon style) are translucent, while the heme groups are solid (spacefilling style). I can rotate it and easily see how the four heme groups are placed in the tertiary structures of the four protein strands.

for 10 years I have been giving an introduction into protein structure at the Zuyd applied university (two short lectures, two short practicals).

We have been using Proteopedia, because it is Open, it is free, it is interactive, and is powered by Jmol […]

[Original post on social.edu.nl]

This is the new reality of drug discovery. What are your six impossible things?

For scientists, it’s :

- Planning new discovery programs

- Coordinating work with scientists across multiple labs and CROs

- Running synthesis requests and assays

- Generating, collecting, and analyzing all the data

...and then doing it all over again.

YouTube video by Aspen Biosciences 6 Impossible Things

The pandemic taught us we can do six impossible things before breakfast —like getting new medicines to patients faster by collaborating across time zones 24/7.

Now, that "impossible" pace is the daily routine.

#DrugDiscovery #Biotech #Science #Rnd #Pharma #Innovation

Watch the video on our YouTube channel for a brief preview.
youtu.be/6fPV1bIttnA?...

Our latest whitepaper contains case studies, examples and implementation strategies that you can apply to improve your drug discovery operations. aspenbiosciences.com/whitepapers/...

The Digital Transformation Roadmap - Aspen Biosciences The whitepaper explores the impact of digital transformation on small molecule drug discovery, highlighting strategies to enhance R&D efficiency and reduce costs. It includes case studies,and practica...

#DigitalTransformation is the process of applying technologies like #AI, #automation and advanced analytics to fundamentally change #DrugDiscovery, in ways that measurably reduce costs and timelines, improve capital efficiency and create a more lean and agile research organization.

Post Image

In our series "Across The Great Divide" we're taking a look at the "Great Divide" between drug discovery and drug development projects and how drug discovery project planning can improve the capital efficiency of your programs and the…

https://aspenbiosciences.com/across-the-great-divide-part-2/

2025 Welch Award honors chemical biologists Recipients Schreiber and Schultz will each receive $500K prize for work on chemical probes, unnatural amino acids, and new therapeutics

Chemists Stuart Schreiber of Harvard University and Arena BioWorks and Peter Schultz of @scripps.edu will split the 2025 Welch Award in Chemistry for their work in the field of chemical biology. cen.acs.org/people/award... #chemsky🧪

4 takeaways from the MAHA commission’s report on children’s health The MAHA commission's assessment of children's health mirrored RFK Jr.'s familiar targets. The question now is what remedies they will recommend.

Health secretary RFK Jr. names familiar culprits for the "sickest generation," even where evidence is lacking

www.statnews.com/2025/05/22/r...

YouTube video by Recursion Recursion's "Era of TechBio" Panel at JPM Featuring Dean Li, Kimberly Powell, Alex Gorsky & Tony Kim

The full panel discussion from our “Era of TechBio” event at #JPM25 is online! Hear from leading voices at the intersection of investment, technology & healthcare discussing the latest wins & remaining obstacles & how breakthroughs like LLMs & AI agents are allowing us to scale. youtu.be/GM9l8Pi8CYs